These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 26140464

  • 1. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.
    Yonemoto Y, Okamura K, Takeuchi K, Ayabe K, Kaneko T, Matsushita M, Tamura Y, Iso T, Okura C, Otsuka K, Inoue H, Takagishi K.
    Mod Rheumatol; 2016; 26(1):24-8. PubMed ID: 26140464
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 3. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU.
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [Abstract] [Full Text] [Related]

  • 4. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
    Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Baker D, Ishii Y, Yoshinari T, GO-FORTH study group.
    Mod Rheumatol; 2016 Jul; 26(4):481-90. PubMed ID: 26474192
    [Abstract] [Full Text] [Related]

  • 6. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 7. Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: partial but detailed results of the GO-FORTH and GO-MONO studies.
    Hayashi M, Kobayakawa T, Takanashi T, Yamazaki H, Ishikawa H, Kanamono T.
    Clin Rheumatol; 2013 Jul; 32(7):961-7. PubMed ID: 23397148
    [Abstract] [Full Text] [Related]

  • 8. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.
    J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
    [Abstract] [Full Text] [Related]

  • 9. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
    Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D.
    Clin Rheumatol; 2014 Sep; 33(9):1239-46. PubMed ID: 25005327
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
    Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel B, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
    [Abstract] [Full Text] [Related]

  • 12. Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.
    Wakabayashi H, Inada H, Nishioka Y, Hasegawa M, Sudo A, Nishioka K.
    Clin Rheumatol; 2017 Apr; 36(4):941-946. PubMed ID: 27942977
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis.
    Kurosawa Y, Ito S, Sakai S, Hasegawa E, Kobayashi D, Abe A, Otani H, Nakazono K, Murasawa A, Narita I, Ishikawa H.
    Intern Med; 2022 Apr; 61(14):2117-2125. PubMed ID: 35850986
    [Abstract] [Full Text] [Related]

  • 14. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
    Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, Noonan L, Lu J, Xu Z, Leu J, Baker D, Bingham CO, GO-FURTHER investigators.
    Ann Rheum Dis; 2014 Dec; 73(12):2152-9. PubMed ID: 24001888
    [Abstract] [Full Text] [Related]

  • 15. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
    Huffstutter JE, Kafka S, Brent LH, Matucci-Cerinic M, Tang KL, Chevrier M, Sprabery T, DeHoratius RJ.
    Curr Med Res Opin; 2017 Apr; 33(4):657-666. PubMed ID: 28035867
    [Abstract] [Full Text] [Related]

  • 16. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis.
    Kanbori M, Suzuka H, Yajima T, Kishino E, Morishige R, Momohara S, Kawakami A, Ota M.
    Mod Rheumatol; 2018 Jan; 28(1):66-75. PubMed ID: 28585869
    [Abstract] [Full Text] [Related]

  • 17. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [Abstract] [Full Text] [Related]

  • 18. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR, van der Heijde DM, Brault Y, Koenig AS, Logeart IS.
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [Abstract] [Full Text] [Related]

  • 19. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R.
    Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
    [Abstract] [Full Text] [Related]

  • 20. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S, Hsia EC.
    J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.